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Abstract
Chronic heart failure (CHF) is a heterogeneous syndrome with a poor prognosis.
Aim of the work – to define predictors of body weight (BW) loss in patients with CHF and a reduced left ventricular ejection 
fraction (LVEF).
Materials and methods. 120 patients with stable CHF and LVEF ≤35 %, II–IV NYHA class were examined. Patients were 
divided into two groups according to the value of BW loss for 6 months: the first group - loss of BW <6 %, the second – ≥6 %.
Results. Out of the 120 patients who were studied, a BW loss of ≥6 % occurred in 59 (49.2 %) patients. According to the results 
of binary logistic regression, predictors of BW loss of ≥6 % in patients with CHF and LVEF≤35 % were: age, coronary heart disease, 
anaemia, and the number of hospitalizations over the last year. People with poorer quality of life, bigger number of points on the Beck 
depression scale and DEFS, with lower levels of physical activity and worse endothelium-dependent vasodilator response; higher sizes 
of the right atrium, right ventricle, and pulmonary artery systolic pressure, E/E’. Higher levels of C-reactive protein (CRP), uric acid are 
associated with a risk of losing BW≥6 %. 
Conclusions. Weight loss ≥6 % is observed in 49.2 % of patients with CHF and LVEF≤35 %. According to multivariate anal-
ysis, independent predictors of BW loss of ≥6 % in patients with CHF and LVEF≤35 % are age, CRP level, III-IV NYHA class, lower 
cholesterol levels, as well as lower rates of flow-dependent vasodilator response and hip circumference.
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1. Introduction
Chronic heart failure (CHF) is a heterogeneous syndrome with a poor prognosis, indepen-
dent predictors of which are neurohormonal activity disorders [1] and the development of cachex-
ia. Cardiac cachexia is known to be a factor in reducing survival in CHF, regardless of other im-
portant variables, such as age, functional class, ejection fraction and physical capabilities [2, 3]. 
According to statistical estimates, the prevalence of unintentional weight loss, defined as a loss 
of 6 % or more of body weight over 6 months, ranges from 12 to 16 % in stable outpatients with 
heart failure (HF) [4], up to 50 % in patients with severe CH [5]. It was found that the mortality 
rate of patients with heart failure and progressive weight loss (BW) can reach 50 % within 18 
months [6]. The pathophysiological mechanisms underlying the loss of BW in patients with CHF 
are not entirely understandable; a number of factors have been identified that lead to an imbal-
ance of catabolic and anabolic processes [7]. On the other hand, the clinical characteristics of 
patients with CHF associated with their loss of BW have been little studied.
Aim of the research – to define the predictors of BW loss in patients with CHF and reduced 
left ventricular ejection fraction (LVEF).
2. Materials and methods
120 hemodynamically stable patients with CHF (97 men, 23 women), 18–75 years old (mean 
age 61±0.86) II–IV NYHA class, with left ventricular ejection fraction (LVEF)≤35 % were exam-
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ined and observed on the basis of the heart failure department of the State Institution “National 
Scientific Center “Institute of Cardiology named after Acad. N. D. Strazhesko” from 2014 to 2019.
Inclusion criteria. The study included patients aged 18–75 years with clinical signs of CHF, 
II–IV NYHA class, LVEF≤35 %, the etiological factor of CHF of which was coronary heart dis-
ease (CHD), including in combination with arterial hypertension (AH) or dilated cardiomyopathy 
(DCMP).
Exclusion criteria. The study did not include patients over the age of 75, with acquired 
and congenital heart defects, gastrointestinal diseases in the acute stage, which limit the ability 
to eat or are characterized by malabsorption syndrome, hypo- and hyperthyroidism, myocardial 
infarction, cerebral stroke, or thromboembolism of pulmonary artery branches up to 3 months 
old, inflammatory and restrictive heart disease, insulin-dependent diabetes mellitus, chronic 
pulmonary heart disease, chronic renal failure stage V, terminal stage of liver failure, bronchial 
asthma or chronic obstructive pulmonary disease of the III–IV stages, oncological and infec-
tious diseases.
The members of the Ethics Commission (extract from protocol No. 2 dated January 20, 2014) 
at the State Institution “National Scientific Center “Institute of Cardiology named after acade-
mician N.D. Strazhesko” of the National Academy of Medical Sciences of Ukraine decided that 
this study would not contradict the main provisions of the GCP, Convention Council of Europe 
on human rights and biomedicine, the Helsinki Declaration of the World Medical Association on 
ethical principles for the conduct of scientific medical research with the participation of man and 
the Law of Ukraine “On Medicines”. All patients signed an informed consent to participate in a 
clinical trial. 
The diagnosis of the underlying disease was determined on the basis of a general clini-
cal examination, special instrumental and laboratory methods. CHF was diagnosed according to 
the recommendations for the diagnosis and treatment of heart failure of the European Society of 
Cardiology and the relevant recommendations of the Association of Cardiology of Ukraine [8, 9]. 
Patients were included in the study in the phase of clinical compensation.
The compulsory examination protocol included electrocardiography, standard echocar-
diography [10], routine laboratory tests (general clinical and biochemical), glomerular filtration 
rate using the EPI formula [11], an assessment of life quality using the Minnesota Living with 
Heart Failure Questionnaire (MLHFQ), an assessment of physical activity level using the Duke 
University questionnaire [12; 13], an assessment of psychological status on the Beck Depres-
sion scale [14], and an assessment of fatigue after physical exertion on the DEFS (Dutch Exer-
tion Fatigue Scale) scale [15]. All patients underwent a general clinical physical examination, 
measuring the thickness of the skin-fat fold (SFF) at four points using a caliper, measuring the 
circumference of the shoulder of an unstrained and tense arm, waist and hip. Evaluation of the 
vasodilating function of the endothelium (flow-mediated vasodilation – FMV) was carried out 
using the ultrasonographic method using a sample with reactive hyperaemia [16]. The functional 
capabilities of the patients were investigated using a standard test with 6-minute walking and 
a standardized test with extension of the lower extremity, the results of which evaluated the 
exposure of the quadriceps femoris. The criterion for the patients distribution into groups was 
the value of weight loss for the last 6 months that preceded the patient inclusion in the study, 
≥6 % according to the European recommendations for the diagnosis and treatment of CHF [8]. 
Information on the dynamics of body weight for the specified period was obtained from medical 
history data and data from medical records of patients. 
Statistical processing of information was carried out using Microsoft Exel programs, IBM 
SPSS Statistics (version 23.0). At the first stage, BW loss factors were tested using binary logis-
tic regression (univariate analysis); uncorrelated odds ratios (ORs) and 95 % confidence intervals 
(CIs) were calculated. At the next stage of our work, statistically significant factors of BW loss 
(p<0.05) were consistently included in the multivariate logistic regression model. In a multidimen-
sional model, factors were excluded when pair correlation gave a high linear correlation coefficient 
(r>0.7). The quality of multivariate logistic regression was determined based on a likelihood com-
parison test. (Likelihood Ratio Test).
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3. Results
Out of the 120 patients who were studied, a BW loss of ≥6 % occurred in 59 (49.2 %) pa-
tients. Their clinical characteristics are presented in Table 1.
Table 1
Clinical characteristics and pharmacotherapy structure of patients with CHF and reduced LVEF
Parameter n %
Number of patients 120 100
Men 97 80.8
CHD 104 86.7
DCMP 15 12.5
Hypertension 102 85.0
MI 49 40.8
AF 69 57.5
II NYHA class 46 38.3
III–IV NYHA class 74 61.7
Anaemia 23 19.2
Diabetes mellitus 34 28.3
ACE inhibitors 70 58.3
BB 94 78.3
MRA 82 68.3
Note: CHD – coronary heart disease; DCMP – dilated cardiomyopathy; MI – myocardial infarction; AF – atrial fibrillation; ACE 
inhibitors – angiotensin-converting enzyme inhibitors; BB – beta-blockers; MRA - mineralocorticoid receptors antagonists
According to the results of binary logistic regression, the predictors of BW loss of ≥6 % in 
patients with CHF and LVEF≤35 % were: age, coronary heart disease, the presence of concomitant 
anaemia, and the number of hospitalizations over the last year. Significantly higher risk of BW loss 
was for people with poorer quality of life and a high NYHA class, a large number of points on the 
Beck depression scale and the fatigue scale after physical exertion. At the same time, patients with 
a higher level of physical activity and a better endothelium-dependent vasodilator response had a 
lower risk of progressive loss of BW (Table 2).
Table 2
Predictors of BW loss ≥6 % over the last 6 months in patients with CHF and reduced LVEF according to 
binary logistic regression analysis (clinical and demographic parameters)
Indicator B (SE) Odds ratio
95 % confidence interval
Р
Lower Upper
1 2 3 4 5 6
Age 0.05 (0.02) 1.05 1.01 1.10 0.018
Men 0.50 (0.47) 1.65 0.66 4.31 0.287
Anaemia 1.05 (0.5) 2.87 1.12 8.05 0.034
Diabetes mellitus 0.54 (0.41) 1.72 0.77 3.85 0.185
CHD 1.21 (0.61) 3.37 1.09 12.67 0.046
CHD combined with hypertension 0.97 (0.53) 2.63 0.94 7.40 0.067
Hypertension 1.07 (0.56) 2.92 0.97 9.67 0.056
DCMP –1.1 (0.62) 0.331 0.099 1.105 0.072
AF 0.01 (0.37) 1.01 0.49 2.08 0.978
II NYHA class –3.41 (0.59) 0.03 0.01 0.10 <0.001
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Note: CHD – coronary heart disease AF – atrial fibrillation; FMV – flow-mediated vasodilation; MLHFQ – The Minnesota Living 
with Heart Failure Questionnaire; DEFS – Dutch Exertion Fatigue Scale
As for the anthropometric parameters, the risk of losing BW ≥ 6 % is lower at higher bicep 
circumferences of the tight and loose arm, waist and hip, SFF thicknesses above the biceps, triceps, 
under the shoulder blade and in the inguinal region (Table 3). 
Table 3
Predictors of BW loss ≥6 % over the last 6 months in patients with CHF and reduced LVEF according to 
binary logistic regression analysis (anthropometric parameters)
Indicator B (SE) Odds ratio
95 % confidence interval
Р
Lower Upper
The circumference of the biceps of relaxed arm –0.31 (0.07) 0.74 0.64 0.83 <0.001
The circumference of the biceps of tight arm –0.31 (0.06) 0.74 0.64 0.83 <0.001
Waist circumference –0.06 (0.02) 0.94 0.91 0.97 <0.001
Hip circumference –0.24 (0.05) 0.79 0.71 0.86 <0.001
SFF thickness over biceps –0.16 (0.05) 0.85 0.77 0.93 0.001
SFF thickness over triceps –0.13 (0.03) 0.88 0.83 0.93 <0.001
SFF thickness under the shoulder blade –0.09 (0.02) 0.92 0.88 0.96 <0.001
SFF thickness in the inguinal region –0.05 (0.02) 0.95 0.91 0.98 0.001
Note: SFF – skin-fat fold
An analysis of laboratory parameters revealed that higher levels of C-reactive protein (CRP), 
uric acid, as well as aspartate aminotransferase (AST) in our patients were significantly associated 
with a risk of losing BW≥6 % among them. It was also found that higher levels of haemoglobin, 
hematocrit, cholesterol, triglycerides and albumin were associated with a lower risk of BW loss 
among studied patients (Table 4).
When studying hemodynamic and echocardiographic parameters, it was determined that 
the risk of losing BW≥6 % in our patients increases with an increase in the size of the right atrium, 
right ventricle, pulmonary artery systolic pressure, and E/E’. At the same time, higher rates of 
diastolic blood pressure, TAPSE, and the ratio of TAPSE to pulmonary arterial systolic pressure 
(PASP) are associated with a reduced risk of loss of BW≥6 % (Table 5).
1 2 3 4 5 6
III–IV NYHA class 3.41 (0.59) 30.39 10.62 111.4 <0.001
MLHFQ score 0.08 (0.02) 1.08 1.05 1.12 <0.001
Duke physical activity index –0.1 (0.02) 0.91 0.87 0.94 <0.001
Beck Depression scale score 0.19 (0.06) 1.20 1.08 1.37 0.002
DEFS score 0.09 (0.02) 1.10 1.05 1.15 <0.001
FMV –0.29 (0.08) 0.75 0.63 0.86 <0.001
Duration of CHF –0.003 (0.005) 0.99 0.99 1.05 0.488
Duration of hypertension 0.01 (0.02) 1.01 0.98 1.05 0.484
Duration of CHD 0.001(0.03) 1.01 0.94 1.06 0.997
Number of hospitalizations over the 
last year 0.47 (0.17) 1.60 1.15 2.30 0.007
Lower limb extension test –0.03 (0.02) 0.97 0.93 1.01 0.130
6 minute walk test –0.007 (0.003) 0.99 0.99 1.00 0.009
Continuation of Table 2
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Table 4
Predictors of BW loss of ≥6 % over the last 6 months in patients with CHF and reduced LVEF according to 
binary logistic regression analysis (laboratory parameters)
Indicator B (SE) Odds ratio
95 % confidence interval
Р
Lower Upper
Haemoglobin –0.02 (0.01) 0.98 0.96 0.99 0.023
Hematocrit –7.2 (3.05) 0.001 0.001 0.30 0.019
Lymphocytes, % –0.02 (0.02) 0.98 0.94 1.02 0.291
Potassium 0.95 (0.56) 2.59 0.90 8.14 0.087
Uric acid 0.004(0.001) 1.004 1.001 1.007 0.006
Bilirubin 0.02 (0.01) 1.02 0.99 1.05 0.199
AST 0.05 (0.02) 1.05 1.02 1.10 0.010
Cholesterol –0.8 (0.22) 0.45 0.28 0.68 <0.001
Triglycerides –1.27 (0.46) 0.28 0.11 0.65 0.006
Albumin –0.18 (0.05) 0.84 0.75 0.92 0.001
CRP 0.42 (0.08) 1.51 1.30 1.80 <0.001
Note: AST – aspartate aminotransferase; CRP – C-reactive protein
Table 5
Predictors of BW loss ≥6 % over the past 6 months in patients with CHF and reduced LVEF according to 
binary logistic regression analysis (hemodynamic and echocardiographic parameters)
Indicator B (SE) Odds ratio
95 % confidence interval
Р
Lower Upper
SBP –0.01(0.02) 0.99 0.96 1.02 0.598
DBP –0.06 (0.03) 0.94 0.89 0.99 0.015
HR –0.01(0.01) 0.99 0.97 1.01 0.338
LVEF –0.04 (0.03) 0.963 0.910 1.019 0.189 
LA 0.43 (0.3) 1.54 0.85 2.79 0.158
LA volume 0.002(0.004) 1.002 0.99 1.01 0.554
LV EDVI 0.008 (0.01) 1.01 0.99 1.02 0.196
LV ESVI –0.001(0.003) 0.99 0.99 1.01 0.625
LV MMI –0.001 (0.005) 0.99 0.99 1.01 0.912
RA 0.5 (0.23) 1.65 1.10 2.66 0.026
RV 0.75 (0.27) 2.12 1.29 3.68 0.005
Е/Е’ 0.11 (0.03) 1.12 1.05 1.20 0.001
ТАPSE –0.19 (0.06) 0.82 0.72 0.92 0.001
TAPSE/PASP –7.39 (2.31) 0.001 0.001 0.04 0.001
PASP 0.08 (0.02) 1.08 1.04 1.13 <0.001
Note: SBP – systolic blood pressure; DBP – diastolic blood pressure; HR- heart rate; LVEF – left ventricular ejection fraction; 
LA – left atrium; LV EDVI – left ventricular end diastolic volume index; LV ESVI – left ventricular end-systolic volume index; 
LV MMI – left ventricular myocardial mass index; RA – right atrium; RV – right ventricle; Е/Е’ – the ratio of the maximum rate of 
early filling of the ventricle to the peak velocity of the lateral part of the mitral ring in the same phase of the cardiac cycle; TAPSE – 
tricuspid annular plane systolic excursion; PASP – pulmonary arterial systolic pressure
In the multivariate regression model, the independent predictors of BW loss ≥6 % in our 
patients were age, CRP level and III-IV NYHA class. However, higher cholesterol, a flow-depen-
dent vasodilator response, and a hip circumference were associated with a lower risk of BW loss 
(Table 6). 
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Table 6
Independent predictors of BW loss ≥6 % over the past 6 months in patients with CHF and reduced LVEF 
according to multivariate analysis
Indicator B (SE) Odds ratio
95 % confidence interval
Р
Lower Upper
Age 0.11 (0.05) 1.11 1.01 1.25 0.045
III–IV NYHA class 4.35 (1.27) 77.15 8.94 1377.73 0.001
CRP 0.62 (0.18) 1.85 1.38 2.83 0.001
FMV % –0.45 (0.2) 0.64 0.40 0.90 0.023
Cholesterol –0.88 (0.40) 0.42 0.17 0.85 0.028
Hip circumference –0.26 (0.09) 0.77 0.62 0.90 0.004
4. Discussion
The study allowed us to confirm data on the association of BW loss in patients with CHF 
and reduced LVEF with age. It is known that muscle loss increases with age, as protein synthesis 
levels in the body decrease, which is a consequence of the ongoing decline in testosterone and 
other anabolic hormones [17, 18]. The loss of BW accompanied CHF is observed much more often 
in patients III–IV NYHA class and is associated with their worst functionality according to the 
6-minute walk test and the assessment of the physical activity index using the DASI questionnaire, 
which is reflected in the worse quality of life of such patients.
The relationship we found between the loss of BW in patients with CHF and impaired func-
tion of the right heart is confirmed in previous studies [19, 20]. According to the data of M. Valento-
va and colleagues, right ventricular failure is hemodynamically associated with venous hyperaemia 
of the gastrointestinal tract. Edema of the intestinal mucosa is associated with abdominal discom-
fort, loss of appetite and postprandial satiety, which entails a deterioration in food intake and a pro-
gression in loss of BW [21]. The second mechanism, according to which venous congestion in the 
intestinal wall can contribute to the development of cardiac cachexia, lies through the production of 
pro-inflammatory cytokines induced by lipopolysaccharides [22]. Researchers suggest that chronic 
intestinal hyperaemia, which is determined by cardiac cachexia, contributes to the constant trans-
location of lipopolysaccharides into the bloodstream even in stable patients. Detection of higher 
serum CRP levels in patients with cachexia that correlated with a larger intestinal wall thickness 
confirms this point of view [21] .
The role of main pathology (CHD) as a predictor of BW loss in patients with CHF can be 
considered from the point of view of the generality of their pathophysiological mechanisms, in 
particular, pro-inflammatory activation. It is known that inflammation plays an important role in 
the progression of atherosclerosis; highly sensitive C-reactive protein is an important risk factor 
for systemic atherosclerosis and is associated with its clinical complications [23, 24]. In the patho-
genesis of heart failure, activation of the immune system also plays a significant role [25], plasma 
CRP level is increased in patients with heart failure. The results of the study show that patients with 
higher CRP show signs of more severe heart failure [26]. There is also evidence that an elevated 
CRP level independently predicts unintended weight loss [5]. CRP is a product of inflammation, 
the synthesis of which is stimulated by the liver in cytokines in response to an inflammatory stimu- 
lus [27]. Interleukin-6 is the main determinant of CRP production [28] in the liver and is produced 
in monocytes, macrophages, endothelial cells, vascular smooth muscle cells, fibroblasts and heart 
myocytes under hypoxic stress [29]. Left ventricular dysfunction, liver or kidney damage caused by 
low cardiac output, hypoperfusion, hypoxia and venous congestion can stimulate the production of 
interleukin-6 and, therefore, CRP production [30]. It is also possible that the relationship between 
plasma CRP and heart failure is causal. CRP can activate the complement system and stimulate 
the production of cytokines [27], thus causing myocyte apoptosis and contributing to remodeling 
and left ventricular dysfunction. It was shown that CRP inhibits the production of nitric oxide [31] 
and has a direct pro-inflammatory effect on human endothelial cells [32], disrupting their function, 
which is reflected in our results regarding flow-dependent vasodilation. The pathophysiological 
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mechanism of endothelial dysfunction (ED) in CHF is associated with a state of increased oxida-
tive stress in this patient population through a variety of mechanisms – reduced nitric oxide (NO) 
synthesis with the possible involvement of genetic polymorphism of endothelial nitric oxide syn-
thase (eNOS) [33], oxidative NO inactivation [34], increased activity of endothelium-bound xan-
thine oxidase and decreased activity of extracellular superoxide dismutase [35]. Discussing the 
fact of the conjugation of the cachectic process and ED, the latter can be interpreted from at least 
two points of view. On the one hand, ED, reducing the ability to regulate peripheral blood flow in 
skeletal muscles, contributes to the deterioration of perfusion, and, consequently, the conditions for 
the loss of their mass [36]. On the other hand, there is no reason not to evaluate ED in such patients 
as a concomitant factor (the “role of a witness”), since along with a decrease in body weight with 
the clinical progression of CHF, the state of endothelial function worsens to the same extent [37]. 
The role of cholesterol as a factor associated with the preservation of BW in CHF can be as-
sociated with the ability to reduce the biological activity of lipopolysaccharides and, consequently, 
the level of inflammatory cytokines [38]. This may partially explain why low serum cholesterol is 
an independent prognostic factor for poor outcome in CHF [39].
Study limitations. A limitation of the study is the fact that the data on changes in body 
weight of some patients were based on their statements due to the lack of measured values in 
medical records, which could potentially be a source of inaccuracies. The lack of information in 
medical data cannot be completely avoided in real clinical practice. However, it was shown that the 
anthropometric data provided personally by the patient are suitable for use in clinical trials, since 
the differences are considered small compared with the measured values [40].
5. Conclusions
1. Weight loss ≥6 % is observed in 49.2 % of patients with CHF and LVEF≤35 %. In addition 
to the older age, its clinical predictors are NYHA class, coronary artery disease, and anaemia.
2. According to a univariate regression analysis, patients with a worse score for quality 
of life, a large number of points on the Beck depression scale and the fatigue scale after physical 
exertion have a higher risk of losing BW≥6 %. The risk of developing progressive BW loss is also 
associated with poorer functional status of patients (6-minute walk test, DASI index) and endothe-
lium-dependent vasodilator response; this risk is reduced at higher values of the bicep circumfer-
ence of a tight and relaxed arm, waist and hip, SFF thicknesses above the biceps, triceps, under the 
shoulder blade and in the inguinal region.
3. The risk of losing BW is associated with higher levels of CRP, uric acid, as well as as-
partate aminotransferase (AST), and decreased levels of haemoglobin, hematocrit, cholesterol, tri-
glycerides, and albumin. The risk of losing BW≥6 % in our patients increases with an increase in 
the size of the right atrium, right ventricle, systolic pressure in the pulmonary artery, and E/E’. 
Higher diastolic blood pressure, TAPSE, and TAPSE to pulmonary systolic pressure ratios are 
associated with a lower risk of BW loss ≥6 %.
4. According to multivariate analysis, independent predictors of BW loss of ≥6 % in patients 
with CHF and LVEF≤35 % are age, CRP, III-IV NYHA class, lower cholesterol levels, as well as 
lower rates of flow-dependent vasodilator response and hip circumference.
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